^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CEACAM5-targeted antibody-drug conjugate

    Related drugs:
    Apply
    Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (NCT05464030)
    Phase 1
    EMD Serono Research & Development Institute, Inc.
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/04/2022
    Primary completion :
    02/27/2026
    Completion :
    02/27/2026
    MSI
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • leucovorin calcium • precemtabart tocentecan (M9140)
    Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (CARMEN-LC06) (NCT05245071)
    Phase 2
    Sanofi
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    06/01/2022
    Primary completion :
    03/06/2024
    Completion :
    09/02/2024
    CEACAM5
    |
    CEACAM5 expression
    |
    tusamitamab ravtansine (SAR408701)
    Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05) (NCT04524689)
    Phase 2
    Sanofi
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    10/26/2020
    Primary completion :
    03/12/2024
    Completion :
    12/30/2024
    CEACAM5
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • tusamitamab ravtansine (SAR408701)
    Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (NCT04394624)
    Phase 2
    Sanofi
    Active, not recruiting
    Last update posted :
    05/01/2024
    Initiation :
    08/31/2020
    Primary completion :
    03/06/2023
    Completion :
    09/30/2024
    CEACAM5
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab) • tusamitamab ravtansine (SAR408701)
    INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 (NCT05703555)
    Phase 2
    Erasmus Medical Center
    Withdrawn
    Last update posted :
    02/28/2024
    Initiation :
    02/16/2024
    Primary completion :
    02/16/2024
    Completion :
    02/16/2024
    CEACAM5
    |
    CEACAM5 expression
    |
    tusamitamab ravtansine (SAR408701)
    SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03) (NCT04154956)
    Phase 3
    Sanofi
    Active, not recruiting
    Last update posted :
    02/08/2024
    Initiation :
    02/06/2020
    Primary completion :
    09/22/2023
    Completion :
    08/26/2026
    CEACAM5
    |
    docetaxel • tusamitamab ravtansine (SAR408701)
    Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer (CARMEN-GC01) (NCT05071053)
    Phase 2
    Sanofi
    Active, not recruiting
    Last update posted :
    02/08/2024
    Initiation :
    11/16/2021
    Primary completion :
    06/23/2023
    Completion :
    06/28/2024
    CEACAM5
    |
    Cyramza (ramucirumab) • tusamitamab ravtansine (SAR408701)
    The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) (NCT05849246)
    Phase 2
    Innovent Biologics (Suzhou) Co. Ltd.
    Not yet recruiting
    Last update posted :
    05/08/2023
    Initiation :
    05/30/2023
    Primary completion :
    04/30/2024
    Completion :
    12/31/2025
    BRAF • ALK • CEACAM5
    |
    BRAF mutation
    |
    cisplatin • carboplatin • Tyvyt (sintilimab) • pemetrexed • tusamitamab ravtansine (SAR408701)
    Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors (NCT03324113)
    Phase 1
    Sanofi
    Completed
    Last update posted :
    01/09/2023
    Initiation :
    10/17/2017
    Primary completion :
    11/18/2022
    Completion :
    12/26/2022
    CEACAM5
    |
    CEACAM5 expression
    |
    tusamitamab ravtansine (SAR408701)